Sign In
Buy MORF
$56.99
+0 (+0%)
At Close: Nov 14, 2024
Morphic to Present at the Wells Fargo Securities 2019 Healthcare Conference
05:00pm, Friday, 30'th Aug 2019
WALTHAM, Mass., Aug. 30, 2019 -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of.
Morphic Announces Corporate Highlights and Second Quarter 2019 Financial Results
10:30am, Monday, 12'th Aug 2019
- Successful IPO provides more than $100 million in gross proceeds to advance leading oral integrin development pipeline and MInT discovery platform - Company remains on track.
The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO
11:26am, Thursday, 27'th Jun 2019
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 26) Odonate Therapeutics Inc (NASDAQ: ODT ) Down In Th
Morphic Announces Pricing of Upsized Initial Public Offering
12:30am, Thursday, 27'th Jun 2019
Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, today announced the pricing of its upsized initial public offer
